Cover Image
市場調查報告書

全球生物模擬市場:各應用領域、地區 - 成長,趨勢,預測(2018年∼2023年)

Global Biosimulation Market - Segmented by Application and Geography - Growth, Trends, and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 390806
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球生物模擬市場:各應用領域、地區 - 成長,趨勢,預測(2018年∼2023年) Global Biosimulation Market - Segmented by Application and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日期: 2018年04月09日 內容資訊: 英文 110 Pages
簡介

全球生物模擬市場,從2018年到2023年的調查期間預計記錄15.9%的年複合成長率。各地區,北美成為這個市場最大的地區。

本報告提供全球生物模擬市場調查,市場概要,各應用領域、地區的市場趨勢,市場規模的變化與預測,市場佔有率,市場促進、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 藥物研發、開發降低成本的必要性
    • 高度的生物模擬工具的必要性
    • 臨床試驗的失敗
    • 由於每人所得上升使醫療支出增加
    • 臨床實驗前的生物模擬的預測準確度的提高
  • 市場阻礙因素
    • 醫護人員的認識不足
    • 標準化流程的缺乏
    • 能處理軟體的技術人員的不足
  • 市場機會
  • 主要課題

第7章 生物模擬市場:各市場區隔

  • 各應用領域
    • 藥物研發
    • 醫藥品開發
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併、收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Rhenovia Pharma
  • Accelrys
  • Certara
  • Genedata
  • Leadscope
  • Compugen
  • Archimedes
  • Simulations Plus, Inc.
  • Schrodinger Inc.
  • Insilico BioTechnology

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55332

The biosimulation market is expected to witness a CAGR of 15.9% during the forecast period. North America dominates the global biosimulation market and is expected to grow at a CAGR over the forecast period.

Need for Low Drug Discovery and Development Costs

The development of new drugs require a huge amount of research and resources. Drug discovery involves enormous investment, and the failure of drug molecule in the later phase results in wastage of effort and cost. Hence, there was a necessity to develop a tool that will outlay the future drug molecule, during the discovery phase. Biosimulation not only helps in predicting the chances of failure of a drug in the development process, but also reduces the cost of any other possible failures by shrinking the set of clinical experiments. This is the major reason that drives the growth of the global biosimulation market. The need for low drug discovery and less development cost is expected to drive this market with a high growth rate in future.

The other factors supporting the growth of the market is the increased accuracy of prediction before an actual trial and increasing healthcare expenditure along with technological advancements in the field of biosimulation.

Shortage of Trained Professionals

Professionals working in the biosimulation market have to possess comprehensive knowledge about the software and science involved in the drug development. Hence the pharmaceutical industry is lacking qualified experts working in this field, and they are looking forward to train their employees, which may consume time and resources. Therefore, the shortage of trained professionals is a limiting factor for the biosimulation market.

In spite of the scope for growth, there are some other factors restraining the global market for biosimulation, which includes lack of awareness among healthcare professionals and of standardized processes.

North America Dominates the Market

North America is anticipated to dominate the global biosimulation market followed by Europe. A large market share of this geographical segment is attributed to factors, such as, growth in the biotechnology and pharmaceutical industry, a large number of ongoing drug development processes, and increasing R&D expenditure by pharmaceutical and biotechnology companies. The Asia Pacific region is also an emerging market where growth is being driven by an increase in the number of CROs.

Key Developments in the Market

July 2017: EQT Partners Inc. acquired Certara, which is a continuation of the convergence between healthcare and technology, as the industry further adopts biosimulation to advance drug development

Major Players: ACCELRYS, DASSAULT SYSTEMES, ARCHIMEDES, CHEMICAL COMPUTING GROUP, CERTARA, COMPUGEN, GENEDATA, LEADSCOPE, RHENOVIA PHARMA AND IN SILICO BIOSCIENCES INC.,amongst others.

Reasons to Purchase this Report

Current and future global biosimulation market outlook in the developed and emerging markets

Various perspectives of the market, with the help of Porter's five forces analysis

The segment expected to dominate the market

The region expected to witness the fastest growth rate during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Need for Low Drug Discovery and Development Costs
    • 6.1.2 Need for Advanced Biosimulation Tools
    • 6.1.3 Failure of Clinical Trials
    • 6.1.4 Increased Spending On Healthcare Due To Rise in Per Capita Income
    • 6.1.5 Rise in the Level of Accuracy of Prediction before Actual Trial
  • 6.2 Market Restraints
    • 6.2.1 Lack of Awareness among Healthcare Professionals
    • 6.2.2 Lack of Standardized Process
    • 6.2.3 Shortfall of Skilled Personnel to Handle the Software
  • 6.3 Opportunities
  • 6.4 Key challenges

7. Market Segmentation

  • 7.1 By Application
    • 7.1.1 Drug Discovery
      • 7.1.1.1 Lead Optimization
      • 7.1.1.2 Lead Validation
      • 7.1.1.3 Target Identification
      • 7.1.1.4 Target Validation
    • 7.1.2 Drug Development
      • 7.1.2.1 Pre-Clinical Testing
      • 7.1.2.2 Clinical Trials
    • 7.1.3 Others
  • 7.2 By Geography
    • 7.2.1 North America
      • 7.2.1.1 United States
      • 7.2.1.2 Canada
      • 7.2.1.3 Mexico
    • 7.2.2 Europe
      • 7.2.2.1 France
      • 7.2.2.2 Germany
      • 7.2.2.3 United Kingdom
      • 7.2.2.4 Italy
      • 7.2.2.5 Spain
      • 7.2.2.6 Rest of Europe
    • 7.2.3 Asia-Pacific
      • 7.2.3.1 China
      • 7.2.3.2 Japan
      • 7.2.3.3 India
      • 7.2.3.4 Australia & New Zealand
      • 7.2.3.5 South Korea
      • 7.2.3.6 Rest of Asia-Pacific
    • 7.2.4 Middle East & Africa
      • 7.2.4.1 GCC
      • 7.2.4.2 South Africa
      • 7.2.4.3 Rest of the Middle East & Africa
    • 7.2.5 South America
      • 7.2.5.1 Brazil
      • 7.2.5.2 Argentina
      • 7.2.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers and Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Rhenovia Pharma
  • 9.2 Accelrys
  • 9.3 Certara
  • 9.4 Genedata
  • 9.5 Leadscope
  • 9.6 Compugen
  • 9.7 Archimedes
  • 9.8 Simulations Plus, Inc.
  • 9.9 Schrodinger Inc.
  • 9.10 Insilico BioTechnology
  • 9.11 List Not Exhaustive

10. Future of the Market

Back to Top